Navigation Links
Experts say direct-to-consumer genetic tests need innovative oversight
Date:10/8/2010

HOUSTON, Oct. 8, 2010 Direct-to-consumer (DTC) genetic tests available from retailers and the Internet let people learn about their genomes without going to a doctor, but they raise the question of who is responsible for oversight and regulation of these tests. Critics worry about safety risks if consumers base important lifestyle or medical decisions on inaccurate or misunderstood test results.

A group of four leading bioethical, legal and medical researchers believes the solution will require an innovative approach that combines premarket studies done before tests enter the market with ongoing postmarket evaluations to confirm how well tests perform once they are in use. Because DTC tests move in a global Internet marketplace, close international cooperation also will be required.

The team, led by Amy L. McGuire of the Center for Medical Ethics and Health Policy at Baylor College of Medicine in Houston, also includes Barbara Evans of the University of Houston (UH) Law Center, Canadian legal expert Timothy Caulfield and Wylie Burke, M.D., of the University of Washington School of Medicine. The group's policy recommendations for DTC genetic tests appear in the Oct. 8 issue of Science magazine, the world's leading journal of original scientific research, global news and commentary.

In their Science article, the authors note that more than 90 percent of the genetic tests now available in the United States have never been through a regulatory review to prove the tests are safe and actually improve human health. A broad consensus exists for some form of regulatory review before new tests enter the market, but potential solutions have been mired in controversy. There are practical barriers to forcing all new genetic tests to go through the same sort of data-intensive premarket review the Food & Drug Administration requires for other medical products, such as drugs.

"Many genetic tests make long-term predictions, and there may be decades of uncertainty before their risks and benefits are fully known," McGuire said. "If we wait until robust premarket data are available, that could delay development of new tests and essentially regulate many DTC companies out of existence."

"We favor a risk-stratified approach that tailors the regulatory requirements to the level of risk a DTC test actually presents," said Evans, who is also co-director of UH's Health Law & Policy Institute. "Genetic testing is not risky in itself, but a test can have significant risks if inaccurate results may lead to serious, irreversible medical decisions or if the test reveals troubling facts that cause psychosocial harm. A recreational test that tells you fascinating facts about who your ancestors were is fundamentally different from a cancer susceptibility test that may panic you to go get preventive surgery."

The article's authors suggest that regulators should pursue a hybrid approach that would continue to let most DTC tests reach the market quickly, with relatively light premarket review requirements. However, they believe that regulators should have the power to keep a higher-risk test off the market until studies confirm it has an acceptable risk-benefit ratio. For all tests, there is a need for enhanced postmarket follow up to confirm that the test is safe and effective, with prompt steps taken to protect the public if any problems emerge.

"The public needs frank disclosure of what is not known about these tests," Evans said.

The group concludes that collaboration among regulatory agencies and informal groups, such as the proposed National Institutes of Health Genetic Testing Registry, could yield the best possible result a market where consumers have ready access to most DTC tests and where innovation is encouraged, yet where sellers of high-risk tests would be required to meet more stringent pre-release standards.


'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert

Related medicine news :

1. Experts advocate realigning type 2 diabetes treatments with diseases natural history
2. Experts urge making cigarettes non-addictive a research priority
3. Decline in Adult Smoking Stalls, Alarming Experts
4. Experts recommend universal screening of newborns for congenital adrenal hyperplasia
5. Nations leading ID experts call for mandatory flu vaccine for all health-care personnel
6. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
7. Experts Predict Normal H1N1 Flu Season This Year
8. Experts Support FDA Panels Backing of New Blood Thinner
9. Sunscreen Concerns Unfounded, Experts Say
10. Experts Issue New Guidelines on Breast Cancer Drugs
11. Experts Believe Many Birth Defects Are Preventable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the ... the grand opening of the Sober College Robert Pfeifer Memorial Learning Center at ... 2-3, and was attended by an overwhelming amount of alumni, family, colleagues and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Mitsubishi Tanabe Pharma Corporation (Head Office: ... Dr. Masayuki Mitsuka ) has presented data that ... intravenously in 10-14 day cycles for 48 weeks experienced ... Functional Rating Scale-Revised (ALSFRS-R). The data were presented at ... Dublin, Ireland . In ...
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The global travel vaccines market to grow ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the sales of ...
(Date:12/9/2016)...  Forge Therapeutics, Inc. today announced a strategic ... TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ... bacterial infections including those caused by drug resistant ... antibacterial target for more than the past 15 ... points has hampered its progress. Forge has been ...
Breaking Medicine Technology: